Arcutis Biotherapeutics Inc. (ARQT) PT Raised to 'Street High' $80 at Cowen

February 1, 2021 9:46 AM EST
Get Alerts ARQT Hot Sheet
Price: $23.33 -1.35%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 11 | New: 8
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cowen analyst Ken Cacciatore raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to a 'Street High' $80.00 (from $55.00) while maintaining an Outperform rating.

The analyst commented, "Arcutis announced positive pivotal Phase III results for ARQ-151 in psoriasis, which even surpassed the impressive Phase IIb data, and we believe firmly establishes the product as the best-in-class topical with superior efficacy/ tolerability. Importantly, the other pipeline programs also continue to progress, representing additional substantial opportunities in AD & seb derm. Our PT moves to $80."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Cowen & Co